vs

Side-by-side financial comparison of Estée Lauder Companies (The) (EL) and Henry Schein (HSIC). Click either name above to swap in a different company.

Estée Lauder Companies (The) is the larger business by last-quarter revenue ($4.2B vs $3.4B, roughly 1.2× Henry Schein). Estée Lauder Companies (The) runs the higher net margin — 3.8% vs 2.9%, a 0.9% gap on every dollar of revenue. On growth, Henry Schein posted the faster year-over-year revenue change (7.7% vs 5.6%). Estée Lauder Companies (The) produced more free cash flow last quarter ($1.0B vs $338.0M). Over the past eight quarters, Henry Schein's revenue compounded faster (4.1% CAGR vs 3.6%).

Estée Lauder was an American businesswoman. She co-founded her eponymous cosmetics company with her husband, Joseph Lauter. Lauder was the only woman on Time magazine's 1998 list of the 20 most influential business geniuses of the 20th century.

Henry Schein, Inc. is an American distributor of health care products and services, with operations in 33 countries and territories. It is the world’s largest provider of health care solutions to office-based dental and medical practitioners. For 14 consecutive years, the company has been named as one of the World's Most Ethical Companies by Ethisphere, most recently in 2025.

EL vs HSIC — Head-to-Head

Bigger by revenue
EL
EL
1.2× larger
EL
$4.2B
$3.4B
HSIC
Growing faster (revenue YoY)
HSIC
HSIC
+2.1% gap
HSIC
7.7%
5.6%
EL
Higher net margin
EL
EL
0.9% more per $
EL
3.8%
2.9%
HSIC
More free cash flow
EL
EL
$679.0M more FCF
EL
$1.0B
$338.0M
HSIC
Faster 2-yr revenue CAGR
HSIC
HSIC
Annualised
HSIC
4.1%
3.6%
EL

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
EL
EL
HSIC
HSIC
Revenue
$4.2B
$3.4B
Net Profit
$162.0M
$101.0M
Gross Margin
76.5%
30.9%
Operating Margin
9.5%
4.7%
Net Margin
3.8%
2.9%
Revenue YoY
5.6%
7.7%
Net Profit YoY
127.5%
7.4%
EPS (diluted)
$0.44
$0.85

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EL
EL
HSIC
HSIC
Q4 25
$4.2B
$3.4B
Q3 25
$3.5B
$3.3B
Q2 25
$3.4B
$3.2B
Q1 25
$3.5B
$3.2B
Q4 24
$4.0B
$3.2B
Q3 24
$3.4B
$3.2B
Q2 24
$3.9B
$3.1B
Q1 24
$3.9B
$3.2B
Net Profit
EL
EL
HSIC
HSIC
Q4 25
$162.0M
$101.0M
Q3 25
$47.0M
$101.0M
Q2 25
$-546.0M
$86.0M
Q1 25
$159.0M
$110.0M
Q4 24
$-590.0M
$94.0M
Q3 24
$-156.0M
$99.0M
Q2 24
$-286.0M
$104.0M
Q1 24
$335.0M
$93.0M
Gross Margin
EL
EL
HSIC
HSIC
Q4 25
76.5%
30.9%
Q3 25
73.4%
30.7%
Q2 25
72.0%
31.4%
Q1 25
75.0%
31.6%
Q4 24
76.1%
31.1%
Q3 24
72.4%
31.3%
Q2 24
71.8%
32.5%
Q1 24
71.9%
31.9%
Operating Margin
EL
EL
HSIC
HSIC
Q4 25
9.5%
4.7%
Q3 25
4.9%
4.9%
Q2 25
-11.4%
4.7%
Q1 25
8.6%
5.5%
Q4 24
-14.5%
4.9%
Q3 24
-3.6%
4.9%
Q2 24
-6.0%
5.1%
Q1 24
13.5%
4.7%
Net Margin
EL
EL
HSIC
HSIC
Q4 25
3.8%
2.9%
Q3 25
1.4%
3.0%
Q2 25
-16.0%
2.7%
Q1 25
4.5%
3.5%
Q4 24
-14.7%
2.9%
Q3 24
-4.6%
3.1%
Q2 24
-7.4%
3.3%
Q1 24
8.5%
2.9%
EPS (diluted)
EL
EL
HSIC
HSIC
Q4 25
$0.44
$0.85
Q3 25
$0.13
$0.84
Q2 25
$-1.52
$0.70
Q1 25
$0.44
$0.88
Q4 24
$-1.64
$0.75
Q3 24
$-0.43
$0.78
Q2 24
$-0.79
$0.80
Q1 24
$0.91
$0.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EL
EL
HSIC
HSIC
Cash + ST InvestmentsLiquidity on hand
$156.0M
Total DebtLower is stronger
$7.3B
$2.3B
Stockholders' EquityBook value
$4.0B
$3.2B
Total Assets
$19.6B
$11.2B
Debt / EquityLower = less leverage
1.82×
0.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EL
EL
HSIC
HSIC
Q4 25
$156.0M
Q3 25
$136.0M
Q2 25
$145.0M
Q1 25
$127.0M
Q4 24
$122.0M
Q3 24
$126.0M
Q2 24
$138.0M
Q1 24
$159.0M
Total Debt
EL
EL
HSIC
HSIC
Q4 25
$7.3B
$2.3B
Q3 25
$7.3B
$2.2B
Q2 25
$7.3B
$2.1B
Q1 25
$7.3B
$2.0B
Q4 24
$7.3B
$1.8B
Q3 24
$7.3B
$1.9B
Q2 24
$7.3B
$1.9B
Q1 24
$7.3B
$2.0B
Stockholders' Equity
EL
EL
HSIC
HSIC
Q4 25
$4.0B
$3.2B
Q3 25
$3.9B
$3.4B
Q2 25
$3.9B
$3.4B
Q1 25
$4.3B
$3.3B
Q4 24
$4.2B
$3.4B
Q3 24
$5.1B
$3.5B
Q2 24
$5.3B
$3.5B
Q1 24
$5.7B
$3.6B
Total Assets
EL
EL
HSIC
HSIC
Q4 25
$19.6B
$11.2B
Q3 25
$19.3B
$11.1B
Q2 25
$19.9B
$10.9B
Q1 25
$19.9B
$10.5B
Q4 24
$19.8B
$10.2B
Q3 24
$21.3B
$10.6B
Q2 24
$21.7B
$10.3B
Q1 24
$22.7B
$10.1B
Debt / Equity
EL
EL
HSIC
HSIC
Q4 25
1.82×
0.71×
Q3 25
1.88×
0.64×
Q2 25
1.89×
0.61×
Q1 25
1.68×
0.59×
Q4 24
1.75×
0.54×
Q3 24
1.44×
0.54×
Q2 24
1.37×
0.54×
Q1 24
1.26×
0.56×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EL
EL
HSIC
HSIC
Operating Cash FlowLast quarter
$1.1B
$381.0M
Free Cash FlowOCF − Capex
$1.0B
$338.0M
FCF MarginFCF / Revenue
24.0%
9.8%
Capex IntensityCapex / Revenue
2.6%
1.3%
Cash ConversionOCF / Net Profit
6.94×
3.77×
TTM Free Cash FlowTrailing 4 quarters
$1.1B
$573.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EL
EL
HSIC
HSIC
Q4 25
$1.1B
$381.0M
Q3 25
$-340.0M
$174.0M
Q2 25
$601.0M
$120.0M
Q1 25
$284.0M
$37.0M
Q4 24
$1.1B
$204.0M
Q3 24
$-670.0M
$151.0M
Q2 24
$889.0M
$296.0M
Q1 24
$534.0M
$197.0M
Free Cash Flow
EL
EL
HSIC
HSIC
Q4 25
$1.0B
$338.0M
Q3 25
$-436.0M
$141.0M
Q2 25
$394.0M
$88.0M
Q1 25
$162.0M
$6.0M
Q4 24
$925.0M
$168.0M
Q3 24
$-811.0M
$117.0M
Q2 24
$672.0M
$259.0M
Q1 24
$359.0M
$156.0M
FCF Margin
EL
EL
HSIC
HSIC
Q4 25
24.0%
9.8%
Q3 25
-12.5%
4.2%
Q2 25
11.6%
2.7%
Q1 25
4.6%
0.2%
Q4 24
23.1%
5.3%
Q3 24
-24.1%
3.7%
Q2 24
17.4%
8.3%
Q1 24
9.1%
4.9%
Capex Intensity
EL
EL
HSIC
HSIC
Q4 25
2.6%
1.3%
Q3 25
2.8%
1.0%
Q2 25
6.1%
1.0%
Q1 25
3.4%
1.0%
Q4 24
3.3%
1.1%
Q3 24
4.2%
1.1%
Q2 24
5.6%
1.2%
Q1 24
4.4%
1.3%
Cash Conversion
EL
EL
HSIC
HSIC
Q4 25
6.94×
3.77×
Q3 25
-7.23×
1.72×
Q2 25
1.40×
Q1 25
1.79×
0.34×
Q4 24
2.17×
Q3 24
1.53×
Q2 24
2.85×
Q1 24
1.59×
2.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EL
EL

Skin Care$2.1B49%
Makeup$1.2B28%
Fragrance$812.0M19%
Hair Care$168.0M4%
Other$31.0M1%

HSIC
HSIC

Global Dental Merchandise$1.2B35%
Global Medical$1.1B31%
Global Dental Equipment$536.0M16%
Global Specialty Products$422.0M12%
Global Technology$173.0M5%
Global Value Added Services$64.0M2%
Equity Method Investee$14.0M0%

Related Comparisons